SQLite Web: event_store.db

Update row 470342 in events

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:3051fe710a1d80c5","evidence_event_ids":["evt_34be322c3a64"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt","company":"Shuttle Pharmaceuticals Holdings, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_71b047e774c77596","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt","content_type":"text/plain","enriched_at":"2026-04-21T09:46:17.102686+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt","source_event_id":"evt_34be322c3a64","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"8e6f3770eb2ca092","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-20","2026-04-21","2026-03-25","2026-05-21","2025-12-31","2026-12-31"],"entities":[{"asset_class":"equity","name":"Shuttle Pharmaceuticals Holdings, Inc.","relevance":"high","symbol":"SHPH","type":"issuer"},{"asset_class":"","name":"Christopher Cooper","relevance":"medium","symbol":"","type":"person"},{"asset_class":"","name":"VirtualShareholderMeeting.com","relevance":"low","symbol":"","type":"website"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal beyond the fact that this DEF 14A was filed.","No details are provided here on the specific director nominees, auditor name, or executive compensation specifics (only that the board recommends \u201cFOR\u201d these proposals).","No financial guidance or quantitative financial implications are disclosed in the provided excerpt beyond the reverse stock split authorization proposal."],"key_facts":["Form DEF 14A proxy statement for Shuttle Pharmaceuticals Holdings, Inc. was filed (proxy statement dated April 20, 2026).","The 2026 Annual Meeting is scheduled for May 21, 2026 at 12:00 p.m. Eastern Time.","The Annual Meeting will be conducted virtually only via live webcast (no in-person meeting).","Stockholders of record at the close of business on March 25, 2026 are entitled to notice of and to vote at the Annual Meeting.","The board recommends voting \u201cFOR\u201d (i) election of director nominees, (ii) ratification of the independent registered public accounting firm for the fiscal year ending December 31, 2026, (iii) approval of executive compensation on an advisory basis, (iv) a proposal authorizing the Board to amend the Certificate of Incorporation to effect one or more reverse stock splits with a cumulative ratio range of 1-for-2 to 1-for-150 (specific ratio determined by the Board after the Annual Meeting) while leaving authorized shares unchanged, and (v) approval of an adjournment if necessary to solicit additional proxies.","The proxy statement uses the full set delivery option under Rule 14a-16(n), with Proxy Materials delivered by mail and posted on a publicly accessible website.","The Proxy Materials include the proxy statement, proxy card, and the Annual Report on Form 10-K for the fiscal year ended December 31, 2025.","The proxy statement is first being mailed to stockholders on or about April 20, 2026."],"numeric_claims":[{"label":"Annual Meeting time (ET)","value":"12:00 p.m."},{"label":"Annual Meeting date","value":"May 21, 2026"},{"label":"Record date","value":"March 25, 2026"},{"label":"Reverse stock split cumulative ratio range","value":"1-for-2 to 1-for-150"}],"primary_claim":"Shuttle Pharmaceuticals Holdings, Inc. filed Form DEF 14A (proxy statement) dated April 20, 2026 for its 2026 Annual Meeting of Stockholders.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Shuttle Pharmaceuticals Holdings, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders. The filing includes proposals to elect directors, ratify the independent auditor, approve executive compensation (advisory), authorize potential reverse stock splits, and approve an adjournment if needed.","topics":["SEC filing","proxy statement","annual meeting","virtual meeting","record date","director nominees","independent auditor","executive compensation","reverse stock split authorization","adjournment of meeting"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 Shuttle Pharmaceuticals Holdings, Inc. \u00b7 Filed 20260420","ticker":"SHPH","tickers":["SHPH"],"title":"SHPH filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1757499/0001493152-26-018117.txt"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel